1. Kahn, SR . The post-thrombotic syndrome. Hematol Am Soc Hematol Educ Program 2016; 2016: 413–418.
Google Scholar | Crossref | Medline2. Farrell, JJ, Sutter, C, Tavri, S, et al. Incidence and interventions for post-thrombotic syndrome. Cardiovasc Diagn Ther 2016; 6: 623–631.
Google Scholar | Crossref | Medline3. Ageno, W, Piantanida, E, Dentali, F, et al. Body mass index is associated with the development of the post-thrombotic syndrome. Thromb Haemostasis 2003; 89: 305–309.
Google Scholar | Crossref | Medline | ISI4. Tick, LW, Kramer, MH, Rosendaal, FR, et al. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemostasis 2008; 6: 2075–2081.
Google Scholar | Crossref | Medline | ISI5. van Dongen, CJ, Prandoni, P, Frulla, M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemostasis 2005; 3: 939–942.
Google Scholar | Crossref | Medline | ISI6. Chitsike, RS, Rodger, MA, Kovacs, MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemostasis 2012; 10: 2039–2044.
Google Scholar | Crossref | Medline7. Dronkers, CEA, Mol, GC, Maraziti, G, et al. Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: a systematic review and meta-analysis. Thromb Haemostasis 2018; 118: 1428–1438.
Google Scholar | Crossref | Medline8. Kahn, SR, Shbaklo, H, Lamping, DL, et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemostasis 2008; 6: 1105–1112.
Google Scholar | Crossref | Medline | ISI9. MacDougall, DA, Feliu, AL, Boccuzzi, SJ, , et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63: S5–S15.
Google Scholar | Crossref | Medline | ISI10. Ashrani, AA, Heit, JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis 2009; 28: 465–476.
Google Scholar | Crossref | Medline | ISI11. Li, R, Yuan, M, Cheng, J, et al. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis. Thromb Res 2020; 196: 340–348.
Google Scholar | Crossref | Medline12. Karathanos, C, Nana, P, Spanos, K, et al. Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord 2021; 9(6): 1568–1576.e1.
Google Scholar | Crossref | Medline13. Kearon, C, Akl, EA, Comerota, AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S–e496S.
Google Scholar | Crossref | Medline | ISI14. Kahn, SR, Comerota, AJ, Cushman, M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation 2014; 130: 1636–1661.
Google Scholar | Crossref | Medline | ISI15. Kahn, SR, Galanaud, JP, Vedantham, S, , et al. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016; 41: 144–153.
Google Scholar | Crossref | Medline16. Tran, HA, Gibbs, H, Merriman, E, et al. New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 2019; 210: 227–235.
Google Scholar | Crossref | Medline17. Villalta, S, Bagatella, P, Piccioli, A, et al. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis 1994; 24: 158a.
Google Scholar18. Campello, E, Spiezia, L, Simion, C, et al. Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Assoc 2020; 9: e018917.
Google Scholar | Crossref | Medline19. Cheung, YW, Middeldorp, S, Prins, MH, et al. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemostasis 2016; 116: 733–738.
Google Scholar | Crossref | Medline20. Jeraj, L, Jezovnik, MK, Poredos, P. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thromb Res 2017; 157: 46–48.
Google Scholar | Crossref | Medline21. Søgaard, M, Nielsen, PB, Skjøth, F, et al. Rivaroxaban versus warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism. Am J Med 2018; 131: 787–794.e4.
Google Scholar | Crossref | Medline22. Utne, KK, Dahm, A, Wik, HS, et al. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res 2018; 163: 6–11.
Google Scholar | Crossref | Medline23. Coleman, CI, Beyer-Westendorf, J, Bunz, TJ, et al. Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism. Clin Appl Thromb Hemost 2018; 24: 575–582.
Google Scholar | SAGE Journals24. De Athayde Soares, R, Matielo, MF, Brochado Neto, FC, et al. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery 2019; 166: 1076–1083.
Google Scholar | Crossref | Medline25. Ferreira, T, Huber, SC, de Moraes Martinelli, B, et al. Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban. Vasc Pharmacol 2020; 124: 106608.
Google Scholar | Crossref | Medline26. Prandoni, P, Ageno, W, Ciammaichella, M, et al. The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. Intern Emerg Med 2020; 15: 447–452.
Google Scholar | Crossref | Medline27. Wik, HS, Kahn, SR, Eriksson, H, et al. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: a long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemostasis 2021; 19: 2495–2503.
Google Scholar | Crossref | Medline28. Prandoni, P, Ageno, W, Mumoli, N, et al. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res 2017; 153: 97–100.
Google Scholar | Crossref | Medline29. Agnelli, G, Gallus, A, Goldhaber, SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor xa inhibitor rivaroxaban (BAY 59-7939). Circulation 2007; 116: 180–187.
Google Scholar | Crossref | Medline | ISI30. Terry, CM, He, Y, Cheung, AK, et al. Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res 2016; 144: 106–112.
Google Scholar | Crossref | Medline31. Rabinovich, A, Cohen, JM, Cushman, M, et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to the risk of post-thrombotic syndrome. J Thromb Haemostasis 2015; 13: 398–408.
Google Scholar | Crossref | Medline32. Hull, RD, Liang, J, Townshend, G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124: 756–765.
Google Scholar | Crossref | Medline | ISI33. Galanaud, JP, Holcroft, CA, Rodger, MA, et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemostasis 2013; 11: 474–480.
Google Scholar | Crossref | Medline | ISI34. Ferreira, AM, Oliveira-Pinto, J, Duarte-Gamas, L, et al. Mid-term patency of iliac venous stenting for post-thrombotic syndrome. Int Angiol 2021; 40: 196–205.
Google Scholar | Crossref | Medline35. Haig, Y, Enden, T, Grøtta, O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol 2016; 3: e64–e71.
Google Scholar | Crossref | Medline | ISI